Latest Hotspot

BioNova Pharmaceuticals' oral Menin inhibitor BN104 has received Fast Track designation from the FDA for the treatment of acute myeloid leukemia

26 October 2023
3 min read

On October 24, 2023, BioNova Pharmaceuticals announced that the U.S. FDA has granted Fast Track Designation to its product BN104 for the treatment of relapsed/refractory acute leukemia. BN104 is a novel and highly selective oral Menin inhibitor developed by BioNova Pharmaceuticals. It has previously been approved for clinical research in the United States and has been granted Orphan Drug Designation by the FDA for the treatment of acute myeloid leukemia (AML).

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

BN104 is a novel and highly selective oral Menin inhibitor designed and discovered by BioNova Pharmaceuticals. Menin inhibitors are currently considered by the academic community to be a potential treatment for global acute leukemia patients carrying MLL gene rearrangements or NPM1 gene mutations. In preclinical research compared with other clinical-stage Menin inhibitors, BN104 has shown superior efficacy and a significantly larger safety window. In April 2023, BN104 received Orphan Drug Designation from the FDA. In August and September 2023, BN104 received Investigational New Drug permissions in China and the United States respectively. On October 19, 2023, BN104 completed its first patient administration in China.

Menin, encoded by the MEN1 gene, mainly exists in the nucleus of cells, serving multiple key roles in biological pathways such as cellular growth regulation, cell cycle control, genomic stability, bone development, and hematopoiesis as a scaffolding protein. It interacts with different binding partners in the nucleus to regulate gene transcription and interacts with various signaling pathways. Research has discovered that Menin inhibitors are effective against leukemia with KMT2A rearrangement (KMT2Ar) and NPM1 mutation (NPM1c), which account for approximately 5-10% and 20-30% of patients with acute lymphoblastic leukemia (ALL) and AML respectively.

图形用户界面, 应用程序

描述已自动生成

According to information disclosed by the Synapse database, as of October 25, 2023, there are a total of 18 investigational drugs targeting Menin, covering 31 indications, involving 16 research institutions, and 23 related clinical trials, with as many as 1274 patents. Acute myeloid leukemia is a blood cancer with generally poor prognosis, where current treatments include chemotherapy and stem cell transplantation. Despite some effective targeted therapies, treatments for patients with KMT2A gene rearrangement and NPM1 mutation subtype are still limited. Menin inhibitors, as a new drug for the treatment of this subtype, have shown promising treatment potential in early clinical trials. Several pharmaceutical companies are already positioning themselves in this market, with the furthest advanced in phase two clinical development. It is anticipated that these inhibitors will be approved soon, providing hope for patients.

图形用户界面, 文本

描述已自动生成

Analysis on the Clinical Research Progress of Nuclear Factor
Analysis on the Clinical Research Progress of Nuclear Factor
26 October 2023
NF-κB is present in almost all animal cells and is a key transcription factor in various biological processes in the human body.
Read →
The KRAS G12C inhibitor IBI351 tablet by Innovent Biologics is set to be included in priority review for the treatment of advanced non-small cell lung cancer
Latest Hotspot
3 min read
The KRAS G12C inhibitor IBI351 tablet by Innovent Biologics is set to be included in priority review for the treatment of advanced non-small cell lung cancer
26 October 2023
The Drug Evaluation Center of the NMPA in China announced on Oct 24, 2023, on its official site, that Innovent Biologics' Category 1 new drug, GFH925 (IBI351), is slated for priority review.
Read →
Advances in Clinical Research on NMDA Receptor Antagonist
Advances in Clinical Research on NMDA Receptor Antagonist
26 October 2023
The N-Methyl-D-Aspartate (NMDA) receptor is a type of ionotropic glutamate receptor that plays a crucial role in excitatory synaptic transmission, plasticity, and excitotoxicity in the central nervous system, closely related to the body's memory, learning, and emotions.
Read →
Arvinas' two AR receptor PROTAC therapies show positive results in Phase 1/2 clinical trials
Latest Hotspot
3 min read
Arvinas' two AR receptor PROTAC therapies show positive results in Phase 1/2 clinical trials
26 October 2023
Arvinas Inc. recently reported positive results for its AR-targeting protein degraders, bavdegalutamide (ARV-110) and ARV-766, in Phase 1/2 trials for mCRPC treatment at ESMO.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.